Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections

•Dalbavancin was associated with fewer 90-day infection-related readmissions compared with standard-of-care (SOC)•Patients receiving dalbavancin had fewer treatment-limiting adverse drug events (ADEs)•Dalbavancin should be considered as an outpatient parenteral antimicrobial therapy (OPAT)-sparing therapy Objective: To assess the efficacy and safety of dalbavancin compared to standard-of-care (SOC) or vancomycin and daptomycin in invasive infections due to suspected or confirmed Gram-positive organisms. Methods: Retrospective cohort of adults who received dalbavancin or SOC on discharge or as an outpatient from 12/2016 to 11/2019. Indications were osteoarticular infection (OAI), infective endocarditis (IE), or other bloodstream infection (BSI). Primary endpoint was 90-day infection-related readmission (IRR); secondary endpoints included time-to-IRR, frequency of adverse drug events (ADEs), and all-cause readmission and mortality. Results: 215 patients were included: 70 (33%) receiving dalbavancin, and 145 (67%) receiving SOC. Indications were OAI (47%), IE (27%), and other BSI (26%). OAI was more common in patients on dalbavancin compared with those receiving SOC (70% vs. 37%, P